Abstract: Provided are an anti-CD40 antibody and a use thereof, such as a mouse, human, chimeric, or humanized antibody specifically binding to CD40, and an antigen-binding fragment thereof, and further provided are a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, and an expression vector and a host cell for expressing the antibody or the antigen-binding fragment thereof. Further provided are a preparation method and a use method for the antibody or the antigen-binding fragment thereof, comprising treating and preventing immune diseases.

Abstract: A ground rail transfer device includes: a support rail provided on the ground and used for unloading a vertical load of a bogie in a rail vehicle; a guide rail provided on the ground and used for driving the bogie to perform a rail transfer operation; and a transition plate provided on the ground and located between a first rail and a second rail which are different in a gauge; wherein a difference between the top surface height of the transition plate and the top surface height of the first rail is equal to a distance between a wheel rim vertex circle and a wheel tread of the rail vehicle.

Abstract: The present application relates to a compound of formula I as a toll-Like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating lung cancer, a pharmaceutical combination of the TLR7 agonist and a tyrosine kinase inhibitor for treating lung cancer, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating lung cancer.

Abstract: A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection.

Abstract: Provided are an antigen-binding polypeptide binding to CD47 or an antigen-binding portion thereof, nucleic acids encoding the polypeptide, vector, cell or pharmaceutical composition. The polypeptide can reduce a tumor or inhibit the growth of tumor cells, treat cancer, promote macrophage phagocytosis, and the like.

Abstract: An anti-IL-36R antibody and a use thereof, in particular, a mouse, chimeric or humanized antibody or an antigen-binding fragment thereof binding to IL-36R; a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, as well as an expression vector and host cell used to express the antibody or the antigen-binding fragment thereof. In addition, a preparation method and a use of the antibody or the antigen-binding fragment thereof, including treatment and prevention of IL-36/IL-36R-mediated diseases and disorders.

Abstract: The present invention relates to a iminosulfanone compound represented by formula (I) as a bromodomain protein inhibitor and a pharmaceutically acceptable salt thereof and to a preparation method, pharmaceutical composition, and medical use thereof.

Abstract: A TYK2 inhibitor compound containing a bicyclic ring and the use thereof in the preparation of a drug for treating or preventing TYK2-related diseases.

Abstract: The present application belongs to the field of pharmaceutical chemistry, and relates to a furo[3,4-b]pyrrole-containing BTK inhibitor, and in particular, to a compound of formula (I), a stereisomer or pharmacologically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof in treating BTK-related diseases.

Abstract: Provided is an isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human CD40. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. An immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the same are further provided.

Abstract: The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing thereof, and a use thereof for inhibiting activity of mutant IDH2 and treating cancer.

Abstract: Provided is an ST2 antigen binding protein, such as a mouse, human, chimeric or humanized antibody or antigen binding fragment thereof that specifically binds to ST2. Also provided are nucleic acid molecules encoding the above-mentioned antibodies and antigen binding fragments thereof, and an expression vector and host cell for expressing the antibodies or antigen binding fragments thereof. Further provided are methods for preparing and using the antibodies and antigen binding fragments thereof. The methods comprise treating and preventing IL33/ST2-mediated related diseases or conditions.

Abstract: A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection.

Abstract: An isolated monoclonal antibody that specifically binds human IL4R?, or an antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. The present disclosure further provides a bispecific molecule, an oncolytic virus and a pharmaceutical composition comprising the antibody or the antigen-binding portion thereof, as well as a treatment method using an Anti-IL4R? antibody or the antigen-binding portion thereof of the disclosure.

Abstract: A quinoline derivative for treating rheumatoid arthritis and a use thereof in preparing a pharmaceutical composition for treating rheumatoid arthritis. In particular, a use of the quinoline derivative 1-[[[4-(4-Fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropanamine in treating rheumatoid arthritis.

Abstract: A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection.

Abstract: A bogie and a rail vehicle, wherein the bogie includes: a framework, a wheel pair connected to the framework, a braking hanger fixed to the framework, a hanger slider used for fixedly connecting to a vehicle wheel braking clamp, and a transmission member; the hanger slider is connected to the braking hanger, and the transmission member is connected to the hanger slider; a first end of the transmission member extends to a side surface of a vehicle wheel in the wheel pair, and the transmission member is used to drive the hanger slider to move along the lateral direction with respect to the braking hanger when the first end is subjected to a thrust applied in the lateral direction by the vehicle wheel, so that the vehicle wheel braking clamp moves to a position corresponding to the vehicle wheel.

Abstract: Disclosed are a class of anti-HBV tetrahydroisoxazolo[4,3-c]pyridine compounds and pharmaceutically acceptable salts thereof or isomers thereof, the compounds being represented by the formula (I).

Abstract: A drug combination containing a TLR7 agonist. Specifically, a drug combination jointly using the compound of formula I acting as a TLR7 agonist and entecavir for the treatment of hepatitis B virus infection and a use thereof, the drug combination having a good anti-hepatitis B virus infection effect.

Abstract: The present invention belongs to the field of medicine, relates to an inhaled preparation of isoglycyrrhizic acid or a salt thereof, and in particular relates to an inhaled preparation of magnesium isoglycyrrhizinate and the use thereof in preparing drugs for treating respiratory system diseases.